DOCSLIB.ORG

Jachetti Suppl Table 1 80814.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jachetti Suppl Table 1 80814.Xlsx Uniprot name Protein name Gene name Peptides OT1 - TPIN-SC(CD62Lhi)/OT1 - TNE-SC(CD62Llo) OT1 - TPIN-SC(CD62Lhi)/OT1 - TPIN-SC(CD62Llo) Log2 (ratio) Counts Log10 (Summed Significance B Log2 (ratio) Counts Log10 (Summed Significance B Intensities) Intensites) O08797 Protein Serpinb9 Serpinb9 5 1,6950 8 6,3029 0,0000 -0,2205 7 6,7278 0,5314 E9Q5W7 L-selectin Sell 2 1,4661 2 5,6553 0,0000 0,9395 4 6,3054 0,3946 Q544R1 Proline synthase co-transcribeD Prosc 2 1,4208 2 6,1679 0,0000 0,5063 2 5,7559 0,7523 bacterial homolog protein O09159 Lysosomal alpha-mannosiDase Man2b1 3 1,1965 2 5,4603 0,0000 NaN 1 5,1854 1,0000 E9PUM4 Talin-2 Tln2 19 1,1659 2 7,2477 0,0000 NaN 0 NaN 1,0000 Q3V157 Signal transDucer anD activator of Stat4 5 0,9376 3 5,7622 0,0000 0,1255 10 6,6896 0,8677 transcription 4 A2RSY6 TRMT1-like protein Trmt1l 2 0,8718 2 5,6063 0,0000 NaN 0 NaN 1,0000 P07356 Annexin A2 Anxa2 16 0,8307 15 6,9356 0,0000 0,9899 19 7,4857 0,4938 Q3UD32 Cathepsin S Ctss 4 0,8148 6 6,4179 0,0000 0,5122 5 6,7013 0,7468 Q8BV49 Pyrin anD HIN Domain-containing Pyhin1 6 0,7389 4 6,3847 0,0001 0,0098 5 6,9368 0,7255 protein 1 A2A4L8 SWI/SNF-relateD matrix- Smarce1 2 0,7367 2 5,5580 0,0001 NaN 1 6,0717 1,0000 associateD actin-DepenDent regulator of chromatin subfamily E member 1 Q7TPR4 Alpha-actinin-1 Actn1 37 0,6753 16 6,8461 0,0000 1,0007 16 7,3022 0,4868 Q6IRU2 Tropomyosin alpha-4 chain Tpm4 8 0,6405 5 6,6265 0,0000 0,5613 5 6,8943 0,8061 E9Q2W5 YTH Domain family protein 3 YthDf2 2 0,6162 2 7,8124 0,0000 NaN 1 7,4648 1,0000 O08738 Caspase-6 Casp6 3 0,5895 2 5,3708 0,0016 NaN 0 NaN 1,0000 Q60790 Ras GTPase-activating protein 3 Rasa3 3 0,5799 3 5,5478 0,0019 NaN 1 5,6291 1,0000 Q9WVA4 Transgelin-2 Tagln2 17 0,5722 26 7,7332 0,0002 2,3596 27 8,0217 0,0369 P17751 Triosephosphate isomerase Tpi1 22 0,5622 29 7,9373 0,0002 1,5262 29 8,2343 0,2174 Q9JKV1 Proteasomal ubiquitin receptor Adrm1 2 0,5270 2 5,7517 0,0047 NaN 0 NaN 1,0000 ADRM1 P09411 Phosphoglycerate kinase 1 Pgk1 37 0,5153 78 8,8397 0,0007 1,2595 46 8,7332 0,3369 Q8VDP4 DBIRD complex subunit KIAA1967 5 0,5130 5 6,1949 0,0059 1,0533 2 5,7730 0,3212 homolog Q3UM45 Protein phosphatase 1 regulatory Ppp1r7 4 0,5031 2 6,0770 0,0070 1,3108 5 6,8583 0,3111 subunit 7 P08882 Granzyme C Gzmc 7 0,5026 3 5,5884 0,0070 -0,8068 8 6,6020 0,1604 G3X8V7 DehyDrogenase/reDuctase SDR Dhrs4 2 0,4776 2 5,5963 0,0104 -0,5076 2 5,8342 0,3140 family member 4 Q8K212 Phosphofurin aciDic cluster Pacs1 2 0,4756 3 7,0835 0,0017 NaN 1 6,8509 1,0000 sorting protein 1 A2APB0 Ras association Domain- Rassf2 2 0,4699 2 5,8000 0,0117 -1,7540 3 6,3781 0,0078 containing protein 2 Q3U5Q7 UMP-CMP kinase 2, Cmpk2 4 0,4640 3 5,8947 0,0128 NaN 1 5,9217 1,0000 mitochonDrial H3BJQ7 PeroxireDoxin-5, mitochonDrial Prdx5 7 0,4244 12 6,8335 0,0051 1,5057 5 6,5802 0,1208 A7VJA4 Glia maturation factor gamma Gmfg 6 0,4203 5 6,5039 0,0241 1,7364 4 6,1648 0,0663 Q62293 T-cell specific GTPase Tgtp 12 0,4172 9 7,4390 0,0059 0,6574 13 7,7309 0,7310 Q921M7 Protein FAM49B Fam49b 14 0,4103 19 7,2253 0,0067 1,6433 17 7,5887 0,1760 P17182 Alpha-enolase Eno1 41 0,4036 91 9,3286 0,0077 1,0965 57 9,0834 0,4275 P12382 6-phosphofructokinase, liver type Pfkl 20 0,4001 17 7,0726 0,0082 0,0401 27 7,5101 0,7513 P70677 Caspase-3 Casp3 9 0,3936 14 6,7163 0,0093 0,7133 8 6,5049 0,5677 P08414 Calcium/calmoDulin-DepenDent Camk4 3 0,3870 2 5,9624 0,0378 NaN 1 5,7048 1,0000 protein kinase type IV P52480 Pyruvate kinase isozymes M1/M2 Pkm2 39 0,3865 67 8,4856 0,0107 1,0119 34 8,8193 0,4797 Q8BGW0 Protein THEMIS Themis 11 0,3861 19 7,2028 0,0107 0,9863 10 7,1067 0,4961 Q3U3B7 Inositol monophosphatase 2 Impa2 4 0,3845 3 5,7489 0,0391 1,1740 4 6,5429 0,2538 Q8BJS4 SUN Domain-containing protein 2 Sun2 8 0,3746 6 6,3396 0,0444 -0,7153 14 7,3637 0,2429 Q8VI63 MOB kinase activator 2 Mob2 3 0,3712 2 5,3867 0,0464 -0,7026 2 5,5207 0,2057 O08529 Calpain-2 catalytic subunit Capn2 4 0,3684 4 6,1532 0,0480 0,6273 3 5,9942 0,6418 Q99JF8 PC4 anD SFRS1-interacting Psip1 2 0,3664 2 6,9437 0,0155 0,3924 3 6,6610 0,8613 protein A2AB61 Formin-like protein 1 Fmnl1 24 0,3600 29 7,5750 0,0174 1,4312 17 7,4182 0,2559 P62852 40S ribosomal protein S25 Rps25 5 0,3595 4 6,8781 0,0175 -0,1072 9 7,3668 0,6291 Q3U7Z6 Phosphoglycerate mutase 1 Pgam1 20 0,3449 33 7,9745 0,0226 2,0025 32 8,3756 0,0852 G5E8N5 L-lactate DehyDrogenase Ldha 29 0,3374 42 8,5068 0,0257 1,2809 56 8,9786 0,3260 Q99LX0 Protein DJ-1 Park7 9 0,3361 13 7,4160 0,0263 1,6947 18 7,5669 0,1597 Q9CWJ9 Bifunctional purine biosynthesis Atic 14 0,3345 9 6,7705 0,0271 0,8891 10 7,4666 0,5612 protein PURH E9Q447 Spectrin alpha chain, brain Spna2 43 0,3237 35 7,4430 0,0324 0,8865 22 7,0579 0,5630 D3Z7R7 Minor histocompatibility protein Hmha1 14 0,2968 21 7,1411 0,0497 1,6972 9 6,9515 0,1590 HA-1 P97310 DNA replication licensing factor Mcm2 26 -0,3947 32 7,4929 0,0418 0,0422 19 7,3342 0,7531 MCM2 P19157 Glutathione S-transferase P 1 Gstp1 10 -0,3980 17 7,7402 0,0402 1,3878 25 7,6731 0,2750 O08749 DihyDrolipoyl DehyDrogenase, Dld 8 -0,4015 10 6,9509 0,0384 -0,3339 10 7,5631 0,4604 mitochonDrial P67778 Prohibitin Phb 12 -0,4144 17 7,3570 0,0326 -0,5685 21 7,8734 0,3161 G3X8T3 Lysosomal protective protein Ctsa 6 -0,4154 6 6,7675 0,0322 1,8389 8 6,9674 0,1203 P29351-2 Tyrosine-protein phosphatase Ptpn6 14 -0,4179 11 7,0530 0,0312 0,3610 11 6,8177 0,9678 non-receptor type 6 G3UWA6 4F2 cell-surface antigen heavy Slc3a2 7 -0,4541 10 6,8165 0,0192 -0,0305 15 7,1149 0,6917 chain A2AJX5 DENN Domain-containing protein Dennd4c 3 -0,4566 2 5,7980 0,0462 NaN 0 NaN 1,0000 4C P08003 Protein DisulfiDe-isomerase A4 PDia4 8 -0,4568 5 6,3880 0,0461 -0,6354 10 6,8522 0,2811 F8WJ19 Interferon-inDuceD very large Gvin1 60 -0,4686 64 7,8146 0,0157 0,5174 47 7,5127 0,8411 GTPase 1 Q9Z2Z6 MitochonDrial Slc25a20 5 -0,4824 2 5,8399 0,0352 -0,0428 4 6,4445 0,6966 carnitine/acylcarnitine carrier protein Q91WD5 NADH DehyDrogenase Ndufs2 4 -0,4839 3 6,0790 0,0346 -0,9711 4 6,6061 0,1048 [ubiquinone] iron-sulfur protein 2, mitochonDrial Q9CZ13 Cytochrome b-c1 complex Uqcrc1 15 -0,4845 12 7,1063 0,0124 -0,9390 13 7,4268 0,1557 subunit 1, mitochonDrial Q543N5 ChloriDe intracellular channel Clic4 7 -0,4914 3 6,3515 0,0319 0,2672 4 6,2372 0,9841 protein 4 Q9CQW2 ADP-ribosylation factor-like Arl8b 3 -0,4975 2 6,2931 0,0298 -0,4700 4 6,8117 0,3727 protein 8B Q922U1 U4/U6 small nuclear Prpf3 3 -0,5014 3 5,2658 0,0286 0,2502 2 5,9562 0,9991 ribonucleoprotein Prp3 O54879 High mobility group protein B3 Hmgb3 4 -0,5144 2 6,0490 0,0247 1,6230 3 6,1522 0,0898 P17918 Proliferating cell nuclear antigen Pcna 13 -0,5150 19 7,4318 0,0079 0,5103 19 7,5336 0,8468 P00405 Cytochrome c oxiDase subunit 2 Mtco2 6 -0,5164 10 7,0302 0,0077 -0,5004 10 7,3351 0,3546 Q9DB77 Cytochrome b-c1 complex Uqcrc2 13 -0,5166 11 7,3178 0,0077 -1,1396 15 7,8109 0,0998 subunit 2, mitochonDrial A2AQR0 Glycerol-3-phosphate GpD2 8 -0,5180 6 6,1713 0,0237 -1,4166 15 6,8479 0,0503 DehyDrogenase, mitochonDrial P50518 V-type proton ATPase subunit E 1 Atp6v1e1 3 -0,5253 5 6,1080 0,0218 NaN 0 NaN 1,0000 P57759 EnDoplasmic reticulum resiDent Erp29 4 -0,5376 3 5,8279 0,0189 -0,6328 8 6,4897 0,2408 protein 29 Q99K70 Ras-relateD GTP-binDing protein C Rragc 2 -0,5477 2 6,0414 0,0168 NaN 1 5,3906 1,0000 P51150 Ras-relateD protein Rab-7a Rab7a 11 -0,5511 19 7,2798 0,0045 0,3136 14 7,3132 0,9928 P62814 V-type proton ATPase subunit B, Atp6v1b2 3 -0,5539 2 6,0009 0,0156 0,5795 2 6,6099 0,6847 brain isoform P29391 Ferritin light chain 1 Ftl1 12 -0,5773 24 7,6472 0,0029 0,2991 9 7,1394 0,9798 P15702 Leukosialin Spn 4 -0,5811 3 6,5475 0,0111 NaN 1 6,2544 1,0000 P04187 Granzyme B(G,H) Gzmb 16 -0,5880 20 7,4775 0,0024 -1,4267 30 7,9187 0,0490 P16460 Argininosuccinate synthase Ass1 3 -0,5982 3 6,1894 0,0090 NaN 1 5,8989 1,0000 Q9QZ85 Interferon-inDucible GTPase 1 Iigp1 5 -0,6094 3 6,5916 0,0078 0,1511 3 6,3210 0,8944 Q9D6J5 NADH DehyDrogenase Ndufb8 2 -0,6221 3 5,9338 0,0066 -0,6035 3 6,2550 0,2568 [ubiquinone] 1 beta subcomplex subunit 8, mitochonDrial Q9D2G2 Dihydrolipoyllysine-residue Dlst 2 -0,6363 4 6,4513 0,0054 -0,7532 7 6,8327 0,2261 succinyltransferase component of 2-oxoglutarate DehyDrogenase complex, mitochonDrial Q9D0M3 Cytochrome c1, heme protein, Cyc1 6 -0,6481 6 6,5436 0,0046 -0,0969 9 6,7691 0,6442 mitochonDrial Q99MN9 Propionyl-CoA carboxylase beta Pccb 3 -0,6998 2 5,6088 0,0022 NaN 1 5,6860 1,0000 chain, mitochonDrial Q9Z1Z0 General vesicular transport factor Uso1 4 -0,7234 2 5,6018 0,0016 NaN 1 5,8059 1,0000 p115 Q9JMH6 ThioreDoxin reDuctase 1, Txnrd1 2 -0,7884 2 6,6378 0,0000 NaN 1 6,4901 1,0000 cytoplasmic E9Q8V6 Protein DennD4a Dennd4a 4 -0,8357 2 5,6765 0,0003 NaN 1 5,0923 1,0000 Q8C129 Leucyl-cystinyl aminopeptiDase Lnpep 22 -0,8386 33 7,6582 0,0000 -0,0181 16 7,0873 0,7020 A2AH25 Rho GTPase-activating protein 1 Arhgap1 3 -0,8565 2 6,5491 0,0002 NaN 0 NaN 1,0000 Q8BH95 Enoyl-CoA hyDratase, Echs1 6 -0,8589 3 6,0123 0,0002 0,7182 9 6,5826 0,5636 mitochonDrial O35405 Phospholipase D3 PlD3 3 -0,8939 2 6,1372 0,0001 NaN 1 6,3228 1,0000 P17047-2 Lysosome-associateD membrane Lamp2 2 -0,9059 4 6,3766 0,0001 -0,5395 3 6,2163 0,2941 glycoprotein 2 Q9D379 EpoxiDe hyDrolase 1 Ephx1 2 -0,9191 2 5,8626 0,0001 NaN 0 NaN 1,0000 P26011 Integrin beta-7 Itgb7 7 -1,0656 6 6,8086 0,0000 NaN 1 6,1814 1,0000 Q8R502 Leucine-rich repeat-containing Lrrc8c 2 -1,1705 2 5,3924 0,0000 NaN 0 NaN 1,0000 protein 8C O35114 Lysosome membrane protein 2 Scarb2 2 -1,2155 2 5,8691 0,0000 NaN 1 5,7700 1,0000 Q60677 Integrin alpha-E Itgae 14 -1,2231 16 7,3844 0,0000 0,7149 3 6,2498 0,5663 Q8C243 Cathepsin D CtsD 8 -1,2690 15 7,3770 0,0000 0,7727 4 7,2140
Load more

Recommended publications
  • Pathway-Specific Dopaminergic Deficits in a Mouse Model of Angelman Syndrome
    Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome Thorfinn T. Riday, … , Benjamin D. Philpot, C.J. Malanga J Clin Invest. 2012;122(12):4544-4554. https://doi.org/10.1172/JCI61888. Research Article Neuroscience Angelman syndrome (AS) is a neurodevelopmental disorder caused by maternal deletions or mutations of the ubiquitin ligase E3A (UBE3A) allele and characterized by minimal verbal communication, seizures, and disorders of voluntary movement. Previous studies have suggested that abnormal dopamine neurotransmission may underlie some of these deficits, but no effective treatment currently exists for the core features of AS. A clinical trial of levodopa (l-DOPA) in AS is ongoing, although the underlying rationale for this treatment strategy has not yet been thoroughly examined in preclinical models. We found that AS model mice lacking maternal Ube3a (Ube3am–/p+ mice) exhibit behavioral deficits that correlated with abnormal dopamine signaling. These deficits were not due to loss of dopaminergic neurons or impaired dopamine synthesis. Unexpectedly, Ube3am–/p+ mice exhibited increased dopamine release in the mesolimbic pathway while also exhibiting a decrease in dopamine release in the nigrostriatal pathway, as measured with fast-scan cyclic voltammetry. These findings demonstrate the complex effects of UBE3A loss on dopamine signaling in subcortical motor pathways that may inform ongoing clinical trials of l-DOPA therapy in patients with AS. Find the latest version: https://jci.me/61888/pdf Research article Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome Thorfinn T. Riday,1,2 Elyse C. Dankoski,1 Michael C. Krouse,3 Eric W. Fish,3 Paul L.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Application of RNA-Seq in Ecotoxicogenomics: Exploring the Effects of Ibuprofen Exposure on Rainbow Trout and C
    Application of RNA-Seq in Ecotoxicogenomics: Exploring the Effects of Ibuprofen Exposure on Rainbow Trout and C. elegans by Lorraine Lok-Lun Yu Brown B.Sc., University of British Columbia, 2007 Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in the Department of Molecular Biology and Biochemistry Faculty of Science Lorraine Lok-Lun Yu Brown 2013 SIMON FRASER UNIVERSITY Fall 2013 Approval Name: Lorraine Lok-Lun Yu Brown Degree: Master of Science Title of Thesis: Application of RNA-Seq in Ecotoxicogenomics: Exploring the Effects of Ibuprofen Exposure on Rainbow Trout and C. elegans Examining Committee: Chair: Nicholas Harden Professor Fiona Brinkman Senior Supervisor Professor William Davidson Supervisor Professor Steven Jones Supervisor Professor Christopher Kennedy Internal Examiner Professor Department of Biological Sciences Date Defended/Approved: December 16, 2013 ii Partial Copyright Licence iii Ethics Statement iv Abstract RNA-Seq was applied in this ecotoxicogenomics study to investigate the effects of ibuprofen in two species, rainbow trout (Oncorhynchus mykiss), a fish routinely used in ecotoxicology tests, and Caenorhabditis elegans, a well-studied nematode with immense genomics information. Exposure to environmentally relevant levels of ibuprofen resulted in gene expression changes relating to stress, prostaglandin synthesis, reproduction and development in both species. In fish, we observed sex-dependent differences in vitellogenin and prostaglandin synthase gene expression, highlighting the importance of genetic sex determination of juvenile fish used in bioassays. In worms, we saw a decrease in progeny production count. Our results suggest that ibuprofen may have negative impacts on reproduction in both species but requires further investigation.
    [Show full text]
  • Supplementary Information Method CLEAR-CLIP. Mouse Keratinocytes
    Supplementary Information Method CLEAR-CLIP. Mouse keratinocytes of the designated genotype were maintained in E-low calcium medium. Inducible cells were treated with 3 ug/ml final concentration doxycycline for 24 hours before performing CLEAR-CLIP. One 15cm dish of confluent cells was used per sample. Cells were washed once with cold PBS. 10mls of cold PBS was then added and cells were irradiated with 300mJ/cm2 UVC (254nM wavelength). Cells were then scraped from the plates in cold PBS and pelleted by centrifugation at 1,000g for 2 minutes. Pellets were frozen at -80oC until needed. Cells were then lysed on ice with occasional vortexing in 1ml of lysis buffer (50mM Tris-HCl pH 7.4, 100mM NaCl, 1mM MgCl2, 0.1 mM CaCl2, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS) containing 1X protease inhibitors (Roche #88665) and RNaseOUT (Invitrogen #10777019) at 4ul/ml final concentration. Next, TurboDNase (Invitrogen #AM2238, 10U), RNase A (0.13ug) and RNase T1 (0.13U) were added and samples were incubated at 37oC for 5 minutes with occasional mixing. Samples were immediately placed on ice and then centrifuged at 16,160g at 4oC for 20 minutes to clear lysate. 25ul of Protein-G Dynabeads (Invitrogen #10004D) were used per IP. Dynabeads were pre-washed with lysis buffer and pre- incubated with 3ul of Wako Anti-Mouse-Ago2 (2D4) antibody. The dynabead/antibody mixture was added to the lysate and rocked for 2 hours at 4oC. All steps after the IP were done on bead until samples were loaded into the polyacrylamide gel.
    [Show full text]
  • Transcriptomic Profile Induced in Bone Marrow Mesenchymal Stromal Cells After Interaction with Multiple Myeloma Cells
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 18 Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease Antonio Garcia-Gomez1,2,3, Javier De Las Rivas1, Enrique M. Ocio1,2, Elena Díaz- Rodríguez1, Juan C. Montero1, Montserrat Martín1,3, Juan F. Blanco2, Fermín M. Sanchez-Guijo2,3, Atanasio Pandiella1,2, Jesús F. San Miguel1,2,3 and Mercedes Garayoa1,2,3 1 Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC), Salamanca, Spain 2 Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain 3 Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain Correspondence to: Mercedes Garayoa, email: [email protected] Keywords: multiple myeloma, bone marrow mesenchymal stromal cells, tumor-stroma interactions, gene expression profiling, co- culture techniques, myeloma bone disease Received: January 6, 2014 Accepted: June 2, 2014 Published: June 4, 2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Despite evidence about the implication of the bone marrow (BM) stromal microenvironment in multiple myeloma (MM) cell growth and survival, little is known about the effects of myelomatous cells on BM stromal cells. Mesenchymal stromal cells (MSCs) from healthy donors (dMSCs) or myeloma patients (pMSCs) were co- cultured with the myeloma cell line MM.1S, and the transcriptomic profile of MSCs induced by this interaction was analyzed. Deregulated genes after co-culture common to both d/pMSCs revealed functional involvement in tumor microenvironment cross- talk, myeloma growth induction and drug resistance, angiogenesis and signals for osteoclast activation and osteoblast inhibition.
    [Show full text]
  • The Autism Protein Ube3a/E6AP Remodels Neuronal Dendritic Arborization Via Caspase-Dependent Microtubule Destabilization
    The Journal of Neuroscience, January 10, 2018 • 38(2):363–378 • 363 Neurobiology of Disease The Autism Protein Ube3A/E6AP Remodels Neuronal Dendritic Arborization via Caspase-Dependent Microtubule Destabilization Natasha Khatri,1,2 James P. Gilbert,1 Yuda Huo,1 Roozhin Sharaflari,1 Michael Nee,1 Hui Qiao,1 and XHeng-Ye Man1,2 1Department of Biology, Boston University, Boston, Massachusetts 02215, and 2Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts 02118 UBE3A gene copy number variation and the resulting overexpression of the protein E6AP is directly linked to autism spectrum disorders (ASDs).However,theunderlyingcellularandmolecularneurobiologyremainslessclear.HerewereporttheroleofASD-relatedincreased dosage of Ube3A/E6AP in dendritic arborization during brain development. We show that increased E6AP expression in primary cul- tured neurons leads to a reduction in dendritic branch number and length. The E6AP-dependent remodeling of dendritic arborization results from retraction of dendrites by thinning and fragmentation at the tips of dendrite branches, leading to shortening or removal of dendrites. This remodeling effect is mediated by the ubiquitination and degradation of XIAP (X-linked inhibitors of aptosis protein) by E6AP, which leads to activation of caspase-3 and cleavage of microtubules. In vivo, male and female Ube3A 2X ASD mice show decreased XIAP levels, increased caspase-3 activation, and elevated levels of tubulin cleavage. Consistently, dendritic branching and spine density are reduced in cortical neurons of Ube3A 2X ASD mice. In revealing an important role for Ube3A/E6AP in ASD-related developmental alteration in dendritic arborization and synapse formation, our findings provide new insights into the pathogenesis of Ube3A/E6AP- dependent ASD.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Supplementary Table 9. Functional Annotation Clustering Results for the Union (GS3) of the Top Genes from the SNP-Level and Gene-Based Analyses (See ST4)
    Supplementary Table 9. Functional Annotation Clustering Results for the union (GS3) of the top genes from the SNP-level and Gene-based analyses (see ST4) Column Header Key Annotation Cluster Name of cluster, sorted by descending Enrichment score Enrichment Score EASE enrichment score for functional annotation cluster Category Pathway Database Term Pathway name/Identifier Count Number of genes in the submitted list in the specified term % Percentage of identified genes in the submitted list associated with the specified term PValue Significance level associated with the EASE enrichment score for the term Genes List of genes present in the term List Total Number of genes from the submitted list present in the category Pop Hits Number of genes involved in the specified term (category-specific) Pop Total Number of genes in the human genome background (category-specific) Fold Enrichment Ratio of the proportion of count to list total and population hits to population total Bonferroni Bonferroni adjustment of p-value Benjamini Benjamini adjustment of p-value FDR False Discovery Rate of p-value (percent form) Annotation Cluster 1 Enrichment Score: 3.8978262119731335 Category Term Count % PValue Genes List Total Pop Hits Pop Total Fold Enrichment Bonferroni Benjamini FDR GOTERM_CC_DIRECT GO:0005886~plasma membrane 383 24.33290978 5.74E-05 SLC9A9, XRCC5, HRAS, CHMP3, ATP1B2, EFNA1, OSMR, SLC9A3, EFNA3, UTRN, SYT6, ZNRF2, APP, AT1425 4121 18224 1.18857065 0.038655922 0.038655922 0.086284383 UP_KEYWORDS Membrane 626 39.77128335 1.53E-04 SLC9A9, HRAS,
    [Show full text]
  • Targeting the Ubiquitin System in Glioblastoma', Frontiers in Oncology
    Citation for published version: Licchesi, J 2020, 'Targeting the Ubiquitin System in Glioblastoma', Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.574011 DOI: 10.3389/fonc.2020.574011 Publication date: 2020 Document Version Publisher's PDF, also known as Version of record Link to publication University of Bath Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 24. Sep. 2021 REVIEW published: 25 November 2020 doi: 10.3389/fonc.2020.574011 Targeting the Ubiquitin System in Glioblastoma Nico Scholz 1, Kathreena M. Kurian 2, Florian A. Siebzehnrubl 3 and Julien D. F. Licchesi 1* 1 Department of Biology & Biochemistry, University of Bath, Bath, United Kingdom, 2 Brain Tumour Research Group, Institute of Clinical Neurosciences, University of Bristol, Bristol, United Kingdom, 3 Cardiff University School of Biosciences, European Cancer Stem Cell Research Institute, Cardiff, United Kingdom Glioblastoma is the most common primary brain tumor in adults with poor overall outcome and 5-year survival of less than 5%. Treatment has not changed much in the last decade or so, with surgical resection and radio/chemotherapy being the main options.
    [Show full text]
  • Progression of Pathology in PINK1-Deficient Mouse Brain From
    Torres-Odio et al. Journal of Neuroinflammation (2017) 14:154 DOI 10.1186/s12974-017-0928-0 RESEARCH Open Access Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation Sylvia Torres-Odio1†, Jana Key1†, Hans-Hermann Hoepken1, Júlia Canet-Pons1, Lucie Valek2, Bastian Roller3, Michael Walter4, Blas Morales-Gordo5, David Meierhofer6, Patrick N. Harter3, Michel Mittelbronn3,7,8,9,10, Irmgard Tegeder2, Suzana Gispert1 and Georg Auburger1* Abstract Background: PINK1 deficiency causes the autosomal recessive PARK6 variant of Parkinson’s disease. PINK1 activates ubiquitin by phosphorylation and cooperates with the downstream ubiquitin ligase PARKIN, to exert quality control and control autophagic degradation of mitochondria and of misfolded proteins in all cell types. Methods: Global transcriptome profiling of mouse brain and neuron cultures were assessed in protein-protein interaction diagrams and by pathway enrichment algorithms. Validation by quantitative reverse transcriptase polymerase chain reaction and immunoblots was performed, including human neuroblastoma cells and patient primary skin fibroblasts. Results: In a first approach, we documented Pink1-deleted mice across the lifespan regarding brain mRNAs. The expression changes were always subtle, consistently affecting “intracellular membrane-bounded organelles”.Significant anomalies involved about 250 factors at age 6 weeks, 1300 at 6 months, and more than 3500 at age 18 months in the cerebellar tissue, including Srsf10, Ube3a, Mapk8, Creb3,andNfkbia. Initially, mildly significant pathway enrichment for the spliceosome was apparent. Later, highly significant networks of ubiquitin-mediated proteolysis and endoplasmic reticulum protein processing occurred. Finally, an enrichment of neuroinflammation factors appeared, together with profiles of bacterial invasion and MAPK signaling changes—while mitophagy had minor significance.
    [Show full text]
  • Supplementary Material Table of Contents
    Supplementary M aterial Table of Contents 1 - Online S u pplementary Methods ………………………………………………...… . …2 1.1 Study population……………………………………………………………..2 1.2 Quality control and principal component analysis …………………………..2 1.3 Statistical analyses………………………………………… ………………...3 1.3.1 Disease - specific association testing ……………………………… ..3 1.3.2 Cross - phenotype meta - analysis …………………………………… .3 1.3.3 Model search ……………………………………………………… .4 1.3.4 Novelty of the variants …………………………………………… ..4 1.3.5 Functional Enrichment Analy sis ………………………………… ...4 1.3.6 Drug Target Enrichment Analysis ………………………………… 5 2 - Supplementary Figures………………………………………...………………… . …. 7 3 - Members of the Myositis Genetics Consortium (MYOGEN) ……………………. ..16 4 - Members of the Scleroderma Genetics Consortium ………………… ……………...17 5 - Supplementary References………………………………………………………… . .18 6 - Supplementary Tables………………………………………………………… . ……22 1 Online supplementary m ethods Study population This study was conducted using 12,132 affected subjects and 23 ,260 controls of European des cent population and all of them have been included in previously published GWAS as summarized in Table S1. [1 - 6] Briefly, a total of 3,255 SLE cases and 9,562 ancestry matched controls were included from six countrie s across Europe and North America (Spain, Germany, Netherlands, Italy, UK, and USA). All of the included patients were diagnosed based on the standard American College of Rheumatology (ACR) classification criteria. [7] Previously described GWAS data from 2,363 SSc cases and 5,181 ancestry
    [Show full text]